1.
Smith, K. S. & Rudolph, U. Anxiety and depression: Mouse genetics and pharmacological approaches to the role of GABAA receptor subtypes. Neuropharmacology 62, 54–62 (2012).
2.
Luscher, B., Shen, Q. & Sahir, N. The GABAergic deficit hypothesis of major depressive disorder. Molecular Psychiatry 16, 383–406 (2011).
3.
Balon, R. Mood, anxiety, and physical illness: body and mind, or mind and body? Depression and Anxiety 23, 377–387 (2006).
4.
Kalueff, A. V. & Nutt, D. J. Role of GABA in anxiety and depression. Depression and Anxiety 24, 495–517 (2007).
5.
Cryan, J. F. & Kaupmann, K. Don’t worry ‘B’ happy!: a role for GABAB receptors in anxiety and depression. Trends in Pharmacological Sciences 26, 36–43 (2005).
6.
Holmes, A., Heilig, M., Rupniak, N. M. J., Steckler, T. & Griebel, G. Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends in Pharmacological Sciences 24, 580–588 (2003).
7.
Levine, J., Cole, D. P., Chengappa, K. N. R. & M.D., S. G. Anxiety disorders and major depression, together or apart. Depression and Anxiety 14, 94–104 (2001).
8.
Freund, T. F. Interneuron Diversity series: Rhythm and mood in perisomatic inhibition. Trends in Neurosciences 26, 489–495 (2003).
9.
Strange, P. G. Brain biochemistry and brain disorders. (Oxford University Press, 1992).
10.
Carvalho, A. F. & Van Bockstaele, E. J. Cannabinoid modulation of noradrenergic circuits: Implications for psychiatric disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry 38, 59–67 (2012).
11.
Atwood, B. K., Straiker, A. & Mackie, K. CB2: Therapeutic target-in-waiting. Progress in Neuro-Psychopharmacology and Biological Psychiatry 38, 16–20 (2012).
12.
Hill, A. J., Williams, C. M., Whalley, B. J. & Stephens, G. J. Phytocannabinoids as novel therapeutic agents in CNS disorders. Pharmacology & Therapeutics 133, 79–97 (2012).
13.
Sodium oxybate: a primer for pharmacists in the treatment of narcolepsy. https://www.researchgate.net/profile/Kimberley_Begley2/publication/265473606_Sodium_Oxybate_A_Primer_for_Pharmacists_in_the_Treatment_of_Narcolepsy/links/54dceb110cf25b09b912dd40.pdf.
14.
H. Attarian, O. A. Treatment of disorders of hypersomnolence. 16, 302–302.
15.
N.P. Robertson, K. J. P. Narcolepsy: environment, genes and treatment. 261, 1644–1646 (2014).
16.
Cera, N., Tartaro, A. & Sensi, S. L. Modafinil Alters Intrinsic Functional Connectivity of the Right Posterior Insula: A Pharmacological Resting State fMRI Study. PLoS ONE 9, (2014).
17.
Saper, C. B. & Scammell, T. E. Emerging therapeutics in sleep. Annals of Neurology 74, 435–440 (2013).
18.
Eric J. Olson, K. R. Management of common sleep disorders. 88, 231–238 (2013).
19.
Hoyer, D. & Jacobson, L. H. Orexin in sleep, addiction and more: Is the perfect insomnia drug at hand? Neuropeptides 47, 477–488 (2013).
20.
Carlos H. Schenck, M. W. M. Insights from studying human sleep disorders. 437, 1279–1285 (2005).
21.
Stores, G. Medication for sleep-wake disorders. Archives of Disease in Childhood 88, 899–903 (2003).
22.
Kilduff, T. S. & Peyron, C. The hypocretin/orexin ligand–receptor system: implications for sleep and sleep disorders. Trends in Neurosciences 23, 359–365 (2000).
23.
Brisbare-Roch, C. Promotion of sleep by targeting the orexin system in rats, dogs and humans. 13, 150–155 (2007).
24.
Mark W. Mahowald MD. Pathophysiologic mechanisms in REM sleep behavior disorder. Current Neurology and Neuroscience Reports 7, 167–172 (2007).
25.
Mahowald, M. W. & Schenck, C. H. Dissociated states of wakefulness and sleep. Neurology 42 Suppl. 6, 44–52 (1992).
